CRISPR

CRISPR1-ldlra

ID
ZDB-CRISPR-170913-2
Name
CRISPR1-ldlra
Previous Names
None
Target
Sequence
5' - GGTTGCACTGCCGACTGCCG - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
sd52 ldlra
Expression
Gene expression in Wild Types + CRISPR1-ldlra
No data available
Phenotype
Phenotype resulting from CRISPR1-ldlra
No data available
Phenotype of all Fish created by or utilizing CRISPR1-ldlra
Phenotype Fish Conditions Figures
liver hmgcra expression increased amount, abnormal ldlrasd52/sd52 standard conditions Fig. 2 from Liu et al., 2017
vasculature lipid increased amount, abnormal ldlrasd52/sd52 high cholesterol Fig. 5 from Liu et al., 2017
vasculature lipid increased amount, abnormal ldlrasd52/sd52 standard conditions Fig. 3 from Liu et al., 2017
hepatocyte cellular response to lipopolysaccharide disrupted, abnormal ldlrasd52/sd52 chemical treatment by injection: lipopolysaccharide Fig. 6 from Liu et al., 2017
blood plasma lipid amount, ameliorated ldlrasd52/sd52 high cholesterol, chemical treatment by diet: lomitapide Fig. 5 from Liu et al., 2017
whole organism hmgcra expression increased amount, abnormal ldlrasd52/sd52 standard conditions Fig. 3 from Liu et al., 2017
whole organism ldlra expression decreased amount, abnormal ldlrasd52/sd52 standard conditions Fig. 3 from Liu et al., 2017
blood plasma lipid increased amount, abnormal ldlrasd52/sd52 high cholesterol, chemical treatment by diet: probucol Fig. 5 from Liu et al., 2017
vasculature lipid amount, ameliorated ldlrasd52/sd52 high cholesterol, chemical treatment by diet: lomitapide Fig. 5 from Liu et al., 2017
whole organism cholesterol increased amount, abnormal ldlrasd52/sd52 standard conditions Fig. 3 from Liu et al., 2017
blood plasma very-low-density lipoprotein decreased amount, abnormal ldlrasd52/sd52 standard conditions Fig. 2 from Liu et al., 2017
blood plasma low-density lipoprotein increased amount, abnormal ldlrasd52/sd52 standard conditions Fig. 2 from Liu et al., 2017
whole organism triglyceride increased amount, abnormal ldlrasd52/sd52 standard conditions Fig. 3 from Liu et al., 2017
liver ldlra expression decreased amount, abnormal ldlrasd52/sd52 standard conditions Fig. 2 from Liu et al., 2017
blood plasma cholesterol increased amount, abnormal ldlrasd52/sd52 standard conditions Fig. 2 from Liu et al., 2017
caudal vein lipid increased amount, abnormal ldlrasd52/sd52 standard conditions Fig. 4 from Liu et al., 2017
whole organism fasn expression increased amount, abnormal ldlrasd52/sd52 standard conditions Fig. 3 from Liu et al., 2017
vasculature lipid increased amount, abnormal ldlrasd52/sd52 high cholesterol, chemical treatment by diet: probucol Fig. 5 from Liu et al., 2017
blood plasma lipid increased amount, abnormal ldlrasd52/sd52 high cholesterol Fig. 5 from Liu et al., 2017
caudal vein lipid increased amount, abnormal ldlrasd52/sd52 high cholesterol Fig. 4 from Liu et al., 2017
tolerance induction to lipopolysaccharide disrupted, abnormal ldlrasd52/sd52 chemical treatment by injection: lipopolysaccharide Fig. S3 from Liu et al., 2017
blood plasma triglyceride increased amount, abnormal ldlrasd52/sd52 standard conditions Fig. 2 from Liu et al., 2017
blood plasma lipid increased amount, abnormal ldlrasd52/sd52 standard conditions Fig. 5 from Liu et al., 2017
Citations